Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity

Zymeworks surges on positive Phase 3 Ziihera data in HER2-positive cancer. Discover key catalysts and what’s next for ZYME stock.